WO2020055359A3 - Forme posologique orale de tosylate de sorafénib - Google Patents

Forme posologique orale de tosylate de sorafénib Download PDF

Info

Publication number
WO2020055359A3
WO2020055359A3 PCT/TR2019/050578 TR2019050578W WO2020055359A3 WO 2020055359 A3 WO2020055359 A3 WO 2020055359A3 TR 2019050578 W TR2019050578 W TR 2019050578W WO 2020055359 A3 WO2020055359 A3 WO 2020055359A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
oral dosage
sorafenib tosylate
present
sorafenib
Prior art date
Application number
PCT/TR2019/050578
Other languages
English (en)
Other versions
WO2020055359A2 (fr
Inventor
Ali Turkyilmaz
Ali Ihsan SECKIN
Irem Yenice
Yuksel TOPALOGLU
Original Assignee
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2020055359A2 publication Critical patent/WO2020055359A2/fr
Publication of WO2020055359A3 publication Critical patent/WO2020055359A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une forme posologique orale comprenant du tosylate de sorafénib en tant que principe actif qui présente des propriétés améliorées. La présente invention concerne également un procédé de préparation de ladite composition.
PCT/TR2019/050578 2018-08-10 2019-07-16 Forme posologique orale de tosylate de sorafénib WO2020055359A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/11686 2018-08-10
TR201811686 2018-08-10

Publications (2)

Publication Number Publication Date
WO2020055359A2 WO2020055359A2 (fr) 2020-03-19
WO2020055359A3 true WO2020055359A3 (fr) 2020-06-04

Family

ID=69776588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050578 WO2020055359A2 (fr) 2018-08-10 2019-07-16 Forme posologique orale de tosylate de sorafénib

Country Status (1)

Country Link
WO (1) WO2020055359A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023155182A1 (fr) * 2022-02-21 2023-08-24 北京睿创康泰医药研究院有限公司 Formulation orale de sorafénib ou de donafénib à faible dose et à exposition de forte intensité, et son utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125359A1 (en) * 2001-12-04 2003-07-03 Lyons John F. RAF-MEK-ERK pathway inhibitors to treat cancer
WO2007059154A2 (fr) * 2005-11-14 2007-05-24 Bayer Healthcare Llc Traitement de cancers a resistance acquise a des inhibiteurs de kit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125359A1 (en) * 2001-12-04 2003-07-03 Lyons John F. RAF-MEK-ERK pathway inhibitors to treat cancer
WO2007059154A2 (fr) * 2005-11-14 2007-05-24 Bayer Healthcare Llc Traitement de cancers a resistance acquise a des inhibiteurs de kit

Also Published As

Publication number Publication date
WO2020055359A2 (fr) 2020-03-19

Similar Documents

Publication Publication Date Title
SG11202105850YA (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
WO2015120110A3 (fr) Nouvelles formulations pharmaceutiques
WO2015160843A8 (fr) Activateurs des canaux ioniques et leurs procédés d'utilisation
MX2021006697A (es) Composición y método para el crecimiento del cabello.
PH12020550341A1 (en) Niraparib formulations
EP3279207A4 (fr) Nouveau composé de 4'-thionucléoside, ainsi que son procédé de préparation, composition pharmaceutique comprenant celui-ci et son application
WO2020127819A3 (fr) Composition pharmaceutique comprenant de l'apixaban
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
EP4327880A3 (fr) Forme à l'état solide de succinate de ribociclib
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
IL289763A (en) Compounds, pharmaceutical compounds and methods for preparing compounds and their use
EP3760195A4 (fr) Composition comprenant du 2,3-butanediol en tant que principe actif
WO2019194773A3 (fr) Combinaison contenant de la linagliptine et de la metformine
EP4053152A4 (fr) Kératine bd-13, procédé de préparation, composition pharmaceutique et utilisation de celle-ci
EP3539978A4 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
EP3889160A4 (fr) Composé de thiamine, son procédé de préparation et composition pharmaceutique associée
WO2016006975A3 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
WO2016006974A3 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
EP4053151A4 (fr) Kératine bd-1, procédé de préparation, ainsi que composition pharmaceutique et utilisation de celle-ci
WO2020055359A3 (fr) Forme posologique orale de tosylate de sorafénib
MX2022005798A (es) Red de nanohilos.
WO2017064652A3 (fr) Compositions de dipyridamole faiblement dosées à administration orale et utilisations associées
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EP4053158A4 (fr) Kératine bd-11, procédé de préparation et composition pharmaceutique et utilisation de celle-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19860306

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19860306

Country of ref document: EP

Kind code of ref document: A2